Subjects n | MST months | 1YSR % | p-value | |
All patients | 513 | 4.7 | 21.4 | |
Sex | 0.123 | |||
Female | 141 | 5.7 | 26.8 | |
Male | 372 | 4.7 | 19.3 | |
WHO performance status | <0.0001 | |||
0–1 | 191 | 8.0 | 36.3 | |
2 | 133 | 2.9 | 10.0 | |
3–4 | 73 | 1.1 | 0.0 | |
Smoking status | 0.283 | |||
Never-smoker | 40 | 7.3 | 25.2 | |
Smoker | 448 | 4.6 | 20.3 | |
Histology | 0.429 | |||
Adenocarcinoma | 286 | 4.9 | 24.4 | |
Nonadenocarcinoma | 227 | 4.6 | 17.4 | |
Histology | 0.033 | |||
AD/BAC | 34 | 8.9 | 39.1 | |
Non-AD/BAC | 479 | 4.5 | 20.3 | |
Prior chemotherapy regimens | 0.013 | |||
0 | 42 | 8.0 | 27.0 | |
1 | 170 | 5.3 | 26.1 | |
≥2 | 301 | 3.8 | 16.4 |
MST: median survival time; 1YSR: 1-yr survival rate; WHO: World Health Organization; AD/BAC: adenocarcinoma with bronchioloalveolar features. #: totals and subtotals can be lower than expected in certain cells due to missing values.